{
  "id": 19172923,
  "title": "ProKidney at guggenheim healthcare innovation conference: late-stage kidney push",
  "url": "https://urgent.news/2026/11/09/prokidney-at-guggenheim-healthcare-innovation-conference-late-stage",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T15:32:19.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/prokidney-at-guggenheim-healthcare-innovation-conference-latestage-kidney-push-93CH-5012775"
  },
  "original_language": "en",
  "account": null,
  "summary": "ProKidney (PROK) attended the 3rd Annual Guggenheim Healthcare Innovation Conference on November 9, 2026, to discuss its late-stage kidney cell therapy, rilparencel. The therapy aims to slow kidney decline in patients with advanced chronic kidney disease and diabetes. ProKidney expects to complete enrollment in its Phase III REGEN-007 trial by Q1 2027 and report an accelerated approval readout by Q2 2027. The company has $142 million in cash, which will be sufficient to fund operations until mid-2027. ProKidney targets over 1.1 million U.S. patients with stage 3b or 4 chronic kidney disease and type 2 diabetes, planning a focused launch through 8 to 10 renal partnership network centers.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}